Fig. 5

Cellular pharmacokinetic profiles of CAP, 5′-DFCR, 5′-DFUR and 5-FU in CRC cells after pre-metabolized by HepG2 cells. After HepG2 cells were treated with 500 μM of CAP for 0, 24 or 48 h, the medium of each group was collected and added to CRC cells. For following 0, 2, 4, 6, 12, 24, and 48 h treatments, intracellular concentration–time curves of CAP, 5′-DFCR, 5′-DFUR and 5-FU were plotted. Each point represents mean ± SD (n = 4)